<DOC>
	<DOCNO>NCT00147498</DOCNO>
	<brief_summary>The study 's objective compare efficacy 3 dose level oral CP-690,550 monotherapy ( 5 mg , 15 mg , 30 mg twice daily [ BID ] ) versus placebo administer 6 week treatment sign symptom subject active rheumatoid arthritis ( RA ) .</brief_summary>
	<brief_title>Three Dose Levels CP-690,550 Monotherapy Versus Placebo , Administered Orally Twice Daily ( BID ) 6 Weeks</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>The subject history inadequate response least 1 , 4 , follow DMARDs : sulfasalazine , injectable gold , methotrexate , leflunomide , cyclosporine , thiopurine derivative ( azathioprine 6mercaptopurine ) Current Therapy With Any DMARD Or Biologic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>oral JAK inhibitor</keyword>
	<keyword>clinical trial</keyword>
	<keyword>joint disease</keyword>
	<keyword>anti-Inflammatory agent</keyword>
	<keyword>rheumatic disease</keyword>
	<keyword>DMARD</keyword>
	<keyword>Antirheumatic Agents</keyword>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>Immune System Diseases</keyword>
</DOC>